Intestinal Malabsorption
2
Pipeline Programs
1
Companies
2
Clinical Trials
2 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
1
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
1 companies ranked by most advanced pipeline stage
Elgan PharmaIsrael - Nazareth
2 programs1
1
ELGN-2112Phase 31 trial
ELGN-2112Phase 21 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2025
2026
2027
2028
2029
Elgan PharmaELGN-2112
Elgan PharmaELGN-2112
Clinical Trials (2)
Total enrollment: 420 patients across 2 trials
Efficacy and Safety of ELGN-2112 on Intestinal Malabsorption in Preterm Infants
Start: Feb 2025Est. completion: May 2029360 patients
Phase 3Recruiting
Assess the Safety of ELGN-2112 in Preterm Infants Born Under 26 Weeks GA and IUGR Infants Born 26-32 Weeks GA
Start: Oct 2025Est. completion: Jun 202760 patients
Phase 2Recruiting
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 late-stage (Phase 3) programs, potential near-term approvals
2 actively recruiting trials targeting 420 patients
1 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.